doi:10.1002/ijgo.12902 Nemati M, Nemati S, Taheri AM, Heidari B
Palatin Technologies (the developer) has launched a Phase II study in men with ED who are PDE5 inhibitor non-responders, using a new co-formulation of bremelanotide plus a PDE5i in a single injection
Dehydration is the main risk with diarrhea on GLP-1
Beyond its immediate glycemic effects, Semaglutide slows down gastric emptying, reducing energy intake and post-meal spikes in blood sugar
Madsbad S Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
Eli Lilly rose 4.4% premarket to $1,181, extending Fridays record close, after Phase 3 data showed retatrutide delivered major weight loss and improved obesity-linked conditions